JP2002524528A - ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法 - Google Patents

Info

Publication number

JP2002524528A

JP2002524528A JP2000569830A JP2000569830A JP2002524528A JP 2002524528 A JP2002524528 A JP 2002524528A JP 2000569830 A JP2000569830 A JP 2000569830A JP 2000569830 A JP2000569830 A JP 2000569830A JP 2002524528 A JP2002524528 A JP 2002524528A

Authority

JP

Japan

Prior art keywords

hedgehog

protein

seq

gene

cells

Prior art date

1998-09-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004072 lung Anatomy 0.000 title claims abstract description 137
• 108090000765 processed proteins & peptides Proteins 0.000 title claims description 187
• 102000004196 processed proteins & peptides Human genes 0.000 title claims description 164
• 229920001184 polypeptide Polymers 0.000 title claims description 155
• 239000000203 mixture Substances 0.000 title claims description 60
• 238000009472 formulation Methods 0.000 title description 20
• 238000000034 method Methods 0.000 claims abstract description 138
• 230000012010 growth Effects 0.000 claims abstract description 23
• 241000289669 Erinaceus europaeus Species 0.000 claims abstract 16
• 108090000623 proteins and genes Proteins 0.000 claims description 258
• 102000004169 proteins and genes Human genes 0.000 claims description 127
• 102000003693 Hedgehog Proteins Human genes 0.000 claims description 89
• 108090000031 Hedgehog Proteins Proteins 0.000 claims description 89
• 230000001225 therapeutic effect Effects 0.000 claims description 55
• 239000012634 fragment Substances 0.000 claims description 44
• 230000001105 regulatory effect Effects 0.000 claims description 37
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
• 239000003814 drug Substances 0.000 claims description 33
• 241000282414 Homo sapiens Species 0.000 claims description 22
• 239000003795 chemical substances by application Substances 0.000 claims description 21
• 125000000539 amino acid group Chemical group 0.000 claims description 19
• 150000001413 amino acids Chemical class 0.000 claims description 19
• 230000019491 signal transduction Effects 0.000 claims description 19
• 230000015572 biosynthetic process Effects 0.000 claims description 17
• 230000001404 mediated effect Effects 0.000 claims description 16
• 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 13
• 241001465754 Metazoa Species 0.000 claims description 11
• 238000012423 maintenance Methods 0.000 claims description 8
• 239000002773 nucleotide Substances 0.000 claims description 8
• 125000003729 nucleotide group Chemical group 0.000 claims description 8
• 230000001939 inductive effect Effects 0.000 claims description 6
• 239000000654 additive Substances 0.000 claims description 5
• 238000004113 cell culture Methods 0.000 claims description 5
• 230000011278 mitosis Effects 0.000 claims description 2
• 230000000996 additive effect Effects 0.000 claims 1
• 210000004027 cell Anatomy 0.000 abstract description 178
• 238000011282 treatment Methods 0.000 abstract description 23
• 238000001727 in vivo Methods 0.000 abstract description 22
• 238000000338 in vitro Methods 0.000 abstract description 17
• 230000035755 proliferation Effects 0.000 abstract description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
• 201000010099 disease Diseases 0.000 abstract description 8
• 210000002919 epithelial cell Anatomy 0.000 abstract description 7
• 208000019693 Lung disease Diseases 0.000 abstract description 5
• 230000006378 damage Effects 0.000 abstract description 5
• 108090001047 Fibroblast growth factor 10 Proteins 0.000 abstract description 2
• 102100028412 Fibroblast growth factor 10 Human genes 0.000 abstract description 2
• 210000002782 epithelial mesenchymal cell Anatomy 0.000 abstract description 2
• 244000060234 Gmelina philippensis Species 0.000 description 265
• 235000018102 proteins Nutrition 0.000 description 118
• 101100203200 Danio rerio shha gene Proteins 0.000 description 88
• 101150088976 shh gene Proteins 0.000 description 88
• 230000014509 gene expression Effects 0.000 description 84
• 210000001519 tissue Anatomy 0.000 description 47
• 230000000694 effects Effects 0.000 description 45
• 230000027455 binding Effects 0.000 description 38
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 35
• 150000001875 compounds Chemical class 0.000 description 33
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 32
• 238000011161 development Methods 0.000 description 32
• 230000018109 developmental process Effects 0.000 description 32
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 31
• 239000013598 vector Substances 0.000 description 31
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 30
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 29
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 29
• 210000000981 epithelium Anatomy 0.000 description 29
• -1 e.g. Substances 0.000 description 28
• 239000002502 liposome Substances 0.000 description 28
• 108020003175 receptors Proteins 0.000 description 28
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 26
• 150000007523 nucleic acids Chemical class 0.000 description 26
• 230000011664 signaling Effects 0.000 description 26
• 102000005962 receptors Human genes 0.000 description 25
• 230000004069 differentiation Effects 0.000 description 24
• 238000013518 transcription Methods 0.000 description 24
• 230000035897 transcription Effects 0.000 description 24
• 108020004707 nucleic acids Proteins 0.000 description 23
• 102000039446 nucleic acids Human genes 0.000 description 23
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 21
• 108700008625 Reporter Genes Proteins 0.000 description 21
• 235000001014 amino acid Nutrition 0.000 description 21
• 108020001507 fusion proteins Proteins 0.000 description 21
• 102000037865 fusion proteins Human genes 0.000 description 21
• 239000000126 substance Substances 0.000 description 21
• 239000005557 antagonist Substances 0.000 description 20
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
• 108020004414 DNA Proteins 0.000 description 19
• 229940024606 amino acid Drugs 0.000 description 19
• 238000003556 assay Methods 0.000 description 19
• 239000000047 product Substances 0.000 description 19
• 238000012360 testing method Methods 0.000 description 19
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 18
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 17
• 238000003776 cleavage reaction Methods 0.000 description 16
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 16
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 15
• 125000000217 alkyl group Chemical group 0.000 description 15
• 238000001476 gene delivery Methods 0.000 description 15
• 241001430294 unidentified retrovirus Species 0.000 description 15
• 101000606317 Drosophila melanogaster Protein patched Proteins 0.000 description 14
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 14
• 230000004927 fusion Effects 0.000 description 14
• 230000006698 induction Effects 0.000 description 14
• 150000002632 lipids Chemical class 0.000 description 14
• 210000005265 lung cell Anatomy 0.000 description 14
• 230000002103 transcriptional effect Effects 0.000 description 14
• 238000010249 in-situ analysis Methods 0.000 description 13
• 239000013612 plasmid Substances 0.000 description 13
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 12
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 12
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 12
• 241000700605 Viruses Species 0.000 description 12
• 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 12
• 230000004913 activation Effects 0.000 description 12
• 239000004480 active ingredient Substances 0.000 description 12
• 125000003342 alkenyl group Chemical group 0.000 description 12
• 238000001514 detection method Methods 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 230000007017 scission Effects 0.000 description 12
• 238000012216 screening Methods 0.000 description 12
• 230000003612 virological effect Effects 0.000 description 12
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
• 238000001415 gene therapy Methods 0.000 description 11
• 230000003993 interaction Effects 0.000 description 11
• 238000002703 mutagenesis Methods 0.000 description 11
• 231100000350 mutagenesis Toxicity 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 108010076504 Protein Sorting Signals Proteins 0.000 description 10
• 230000000692 anti-sense effect Effects 0.000 description 10
• 235000012000 cholesterol Nutrition 0.000 description 10
• 235000014113 dietary fatty acids Nutrition 0.000 description 10
• 239000013604 expression vector Substances 0.000 description 10
• 239000000194 fatty acid Substances 0.000 description 10
• 229930195729 fatty acid Natural products 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 108091034117 Oligonucleotide Proteins 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 210000004899 c-terminal region Anatomy 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 210000003238 esophagus Anatomy 0.000 description 9
• 210000003527 eukaryotic cell Anatomy 0.000 description 9
• 150000004665 fatty acids Chemical class 0.000 description 9
• 230000009459 hedgehog signaling Effects 0.000 description 9
• 150000003904 phospholipids Chemical class 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 229940043437 protein kinase A inhibitor Drugs 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 241000701161 unidentified adenovirus Species 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 239000004615 ingredient Substances 0.000 description 8
• 108020004999 messenger RNA Proteins 0.000 description 8
• 239000003921 oil Substances 0.000 description 8
• 235000019198 oils Nutrition 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 230000006798 recombination Effects 0.000 description 8
• 238000005215 recombination Methods 0.000 description 8
• 239000004094 surface-active agent Substances 0.000 description 8
• 210000003437 trachea Anatomy 0.000 description 8
• 239000013603 viral vector Substances 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 7
• 239000011575 calcium Substances 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000002255 enzymatic effect Effects 0.000 description 7
• 230000003278 mimic effect Effects 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 238000000059 patterning Methods 0.000 description 7
• 239000003755 preservative agent Substances 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 241000701022 Cytomegalovirus Species 0.000 description 6
• 101150099234 FGF10 gene Proteins 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 210000004712 air sac Anatomy 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 210000003123 bronchiole Anatomy 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000010586 diagram Methods 0.000 description 6
• 239000000975 dye Substances 0.000 description 6
• 210000002257 embryonic structure Anatomy 0.000 description 6
• 210000001900 endoderm Anatomy 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 239000006210 lotion Substances 0.000 description 6
• 239000002674 ointment Substances 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 239000012656 protein kinase A inhibitor Substances 0.000 description 6
• 108010065251 protein kinase modulator Proteins 0.000 description 6
• 230000002797 proteolythic effect Effects 0.000 description 6
• 230000001177 retroviral effect Effects 0.000 description 6
• 150000007970 thio esters Chemical class 0.000 description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 5
• 241000287828 Gallus gallus Species 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 101710181812 Methionine aminopeptidase Proteins 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 150000001298 alcohols Chemical class 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000009918 complex formation Effects 0.000 description 5
• 239000002537 cosmetic Substances 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 238000004091 panning Methods 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 210000001236 prokaryotic cell Anatomy 0.000 description 5
• 230000000241 respiratory effect Effects 0.000 description 5
• 210000002345 respiratory system Anatomy 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000002562 thickening agent Substances 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 238000010361 transduction Methods 0.000 description 5
• 230000026683 transduction Effects 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• 101800001415 Bri23 peptide Proteins 0.000 description 4
• 101800000655 C-terminal peptide Proteins 0.000 description 4
• 102400000107 C-terminal peptide Human genes 0.000 description 4
• 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 4
• 101710132601 Capsid protein Proteins 0.000 description 4
• 101710094648 Coat protein Proteins 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
• 239000004166 Lanolin Substances 0.000 description 4
• 101710125418 Major capsid protein Proteins 0.000 description 4
• 101150111110 NKX2-1 gene Proteins 0.000 description 4
• 101710141454 Nucleoprotein Proteins 0.000 description 4
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
• 101710083689 Probable capsid protein Proteins 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 241000700584 Simplexvirus Species 0.000 description 4
• 229930182558 Sterol Natural products 0.000 description 4
• 101150019524 WNT2 gene Proteins 0.000 description 4
• 108700020986 Wnt-2 Proteins 0.000 description 4
• 102000052556 Wnt-2 Human genes 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 125000004442 acylamino group Chemical group 0.000 description 4
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 125000003368 amide group Chemical group 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000000423 cell based assay Methods 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 125000004093 cyano group Chemical group *C#N 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 230000005014 ectopic expression Effects 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 210000002744 extracellular matrix Anatomy 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 239000010408 film Substances 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 229960002449 glycine Drugs 0.000 description 4
• 125000000623 heterocyclic group Chemical group 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 229930195733 hydrocarbon Natural products 0.000 description 4
• 150000002430 hydrocarbons Chemical class 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• 235000019388 lanolin Nutrition 0.000 description 4
• 229940039717 lanolin Drugs 0.000 description 4
• 210000000982 limb bud Anatomy 0.000 description 4
• 150000002634 lipophilic molecules Chemical class 0.000 description 4
• 230000007774 longterm Effects 0.000 description 4
• 230000007905 lung morphogenesis Effects 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 4
• 229930182817 methionine Natural products 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 230000024799 morphogenesis of a branching structure Effects 0.000 description 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
• 238000004806 packaging method and process Methods 0.000 description 4
• 239000002304 perfume Substances 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000002685 pulmonary effect Effects 0.000 description 4
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 210000002460 smooth muscle Anatomy 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 238000001228 spectrum Methods 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 150000003432 sterols Chemical class 0.000 description 4
• 235000003702 sterols Nutrition 0.000 description 4
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
• WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 4
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 101100522123 Caenorhabditis elegans ptc-1 gene Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 108050001049 Extracellular proteins Proteins 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 102000005720 Glutathione transferase Human genes 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 3
• 102100034353 Integrase Human genes 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 108091092724 Noncoding DNA Proteins 0.000 description 3
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
• 108010033276 Peptide Fragments Proteins 0.000 description 3
• 102000007079 Peptide Fragments Human genes 0.000 description 3
• 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 3
• 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 102100031083 Uteroglobin Human genes 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 230000000468 autoproteolytic effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 101150067309 bmp4 gene Proteins 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000025084 cell cycle arrest Effects 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 101150118300 cos gene Proteins 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 238000007878 drug screening assay Methods 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 239000003792 electrolyte Substances 0.000 description 3
• 108010078428 env Gene Products Proteins 0.000 description 3
• 239000003925 fat Substances 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 229930195712 glutamate Natural products 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 230000007040 lung development Effects 0.000 description 3
• 229920002521 macromolecule Polymers 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 108091005601 modified peptides Proteins 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000002751 oligonucleotide probe Substances 0.000 description 3
• 210000000287 oocyte Anatomy 0.000 description 3
• CSHWQDPOILHKBI-UHFFFAOYSA-N perylene Chemical compound C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 150000003505 terpenes Chemical class 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
• BDVFVCGFMNCYPV-NSHDSACASA-N 1-(5-isoquinolinesulfonyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12 BDVFVCGFMNCYPV-NSHDSACASA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 206010006458 Bronchitis chronic Diseases 0.000 description 2
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 230000004568 DNA-binding Effects 0.000 description 2
• 241000252212 Danio rerio Species 0.000 description 2
• 101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 2
• 108700018846 Drosophila hh Proteins 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 102100029727 Enteropeptidase Human genes 0.000 description 2
• 108010013369 Enteropeptidase Proteins 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 241000724791 Filamentous phage Species 0.000 description 2
• 206010016717 Fistula Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 101100203205 Homo sapiens SHH gene Proteins 0.000 description 2
• 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• ZHEHVZXPFVXKEY-RUAOOFDTSA-N KT 5720 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@@H]1C[C@](C(=O)OCCCCCC)(O)[C@@]4(C)O1 ZHEHVZXPFVXKEY-RUAOOFDTSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 239000000232 Lipid Bilayer Substances 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 241000713869 Moloney murine leukemia virus Species 0.000 description 2
• 241000713333 Mouse mammary tumor virus Species 0.000 description 2
• ZKZXNDJNWUTGDK-UHFFFAOYSA-N N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide Chemical compound C1=CC(Br)=CC=C1C=CCNCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12 ZKZXNDJNWUTGDK-UHFFFAOYSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 201000010001 Silicosis Diseases 0.000 description 2
• 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 241000255588 Tephritidae Species 0.000 description 2
• 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 102000013814 Wnt Human genes 0.000 description 2
• 108050003627 Wnt Proteins 0.000 description 2
• 241000269370 Xenopus <genus> Species 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• 229960004365 benzoic acid Drugs 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 2
• 229960005263 bucladesine Drugs 0.000 description 2
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 238000005266 casting Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000008614 cellular interaction Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 208000007451 chronic bronchitis Diseases 0.000 description 2
• WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
• 235000015165 citric acid Nutrition 0.000 description 2
• 229960004106 citric acid Drugs 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 108091036078 conserved sequence Proteins 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 210000002308 embryonic cell Anatomy 0.000 description 2
• NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
• 101150033912 gli3 gene Proteins 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 230000036252 glycation Effects 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 150000004001 inositols Chemical class 0.000 description 2
• 230000008611 intercellular interaction Effects 0.000 description 2
• 230000031146 intracellular signal transduction Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• BFIWZEKPARJYJE-UHFFFAOYSA-N isoquinoline-5-sulfonamide Chemical compound N1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1 BFIWZEKPARJYJE-UHFFFAOYSA-N 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 235000015110 jellies Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
• 229960002216 methylparaben Drugs 0.000 description 2
• 230000000921 morphogenic effect Effects 0.000 description 2
• 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 210000004898 n-terminal fragment Anatomy 0.000 description 2
• 210000004897 n-terminal region Anatomy 0.000 description 2
• 210000001020 neural plate Anatomy 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 206010035653 pneumoconiosis Diseases 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• 235000020004 porter Nutrition 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000007261 regionalization Effects 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 229940043267 rhodamine b Drugs 0.000 description 2
• 102220240796 rs553605556 Human genes 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000002023 somite Anatomy 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 210000005127 stratified epithelium Anatomy 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 230000008467 tissue growth Effects 0.000 description 2
• 230000002463 transducing effect Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000008189 vertebrate development Effects 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 230000009278 visceral effect Effects 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
• JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
• DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
• NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 1
• CTTVWDKXMPBZMQ-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]undecan-1-one Chemical compound CCCCCCCCCCC(=O)c1ccc2cc(ccc2c1)N(C)C CTTVWDKXMPBZMQ-UHFFFAOYSA-N 0.000 description 1
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
• RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
• MPPQGYCZBNURDG-UHFFFAOYSA-N 2-propionyl-6-dimethylaminonaphthalene Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CC)=CC=C21 MPPQGYCZBNURDG-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101100325793 Arabidopsis thaliana BCA2 gene Proteins 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090000363 Bacterial Luciferases Proteins 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000009079 Bronchial Spasm Diseases 0.000 description 1
• 208000014181 Bronchial disease Diseases 0.000 description 1
• 201000004813 Bronchopneumonia Diseases 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 101710104316 Cell surface-binding protein Proteins 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 241001559589 Cullen Species 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 101100522126 Danio rerio ptch1 gene Proteins 0.000 description 1
• 239000004287 Dehydroacetic acid Substances 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 108700001637 Drosophila ci Proteins 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 101100084900 Drosophila melanogaster Rpn11 gene Proteins 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000289659 Erinaceidae Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 239000004258 Ethoxyquin Substances 0.000 description 1
• 102100029777 Eukaryotic translation initiation factor 3 subunit M Human genes 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 1
• 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
• 101001012700 Homo sapiens Eukaryotic translation initiation factor 3 subunit M Proteins 0.000 description 1
• 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
• 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
• 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 108010038049 Mating Factor Proteins 0.000 description 1
• 206010027145 Melanocytic naevus Diseases 0.000 description 1
• 241001599018 Melanogaster Species 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101001055252 Mus musculus Indian hedgehog protein Proteins 0.000 description 1
• 101000616468 Mus musculus Sonic hedgehog protein Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 description 1
• 101800000597 N-terminal peptide Proteins 0.000 description 1
• 102400000108 N-terminal peptide Human genes 0.000 description 1
• 208000007256 Nevus Diseases 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 101150012394 PHO5 gene Proteins 0.000 description 1
• 241000051107 Paraechinus aethiopicus Species 0.000 description 1
• 102000000017 Patched Receptors Human genes 0.000 description 1
• 108010069873 Patched Receptors Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 101710113849 Sonic hedgehog protein Proteins 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
• JPBAVLUULZJFFO-JENHRLMUSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JPBAVLUULZJFFO-JENHRLMUSA-N 0.000 description 1
• ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000000058 anti acne agent Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 229940124340 antiacne agent Drugs 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
• 239000013602 bacteriophage vector Substances 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 235000010338 boric acid Nutrition 0.000 description 1
• 229930006742 bornane Natural products 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• BEWYHVAWEKZDPP-UHFFFAOYSA-N camphane Natural products C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000022159 cartilage development Effects 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000034303 cell budding Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000021617 central nervous system development Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229930183167 cerebroside Natural products 0.000 description 1
• RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 239000003245 coal Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 210000002777 columnar cell Anatomy 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 235000019258 dehydroacetic acid Nutrition 0.000 description 1
• 229940061632 dehydroacetic acid Drugs 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000000645 desinfectant Substances 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 208000003401 eosinophilic granuloma Diseases 0.000 description 1
• 230000009786 epithelial differentiation Effects 0.000 description 1
• 230000008202 epithelial morphogenesis Effects 0.000 description 1
• 230000008508 epithelial proliferation Effects 0.000 description 1
• OEZNULIHEQCKJR-UHFFFAOYSA-N ethanol;hydrobromide Chemical compound Br.CCO OEZNULIHEQCKJR-UHFFFAOYSA-N 0.000 description 1
• DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
• 235000019285 ethoxyquin Nutrition 0.000 description 1
• 229940093500 ethoxyquin Drugs 0.000 description 1
• 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• 125000001965 gamma-lactamyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000001280 germinal center Anatomy 0.000 description 1
• 108010087860 glutathione receptor Proteins 0.000 description 1
• 108091005996 glycated proteins Proteins 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960001269 glycine hydrochloride Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229920000591 gum Polymers 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000012203 high throughput assay Methods 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000057243 human FGF10 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 230000000774 hypoallergenic effect Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000010921 in-depth analysis Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000002743 insertional mutagenesis Methods 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000007653 larval development Effects 0.000 description 1
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000008949 local secretion Effects 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000011259 mixed solution Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 230000001002 morphogenetic effect Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000027498 negative regulation of mitosis Effects 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000000276 neural tube Anatomy 0.000 description 1
• VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 235000021048 nutrient requirements Nutrition 0.000 description 1
• 208000007892 occupational asthma Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000005642 phosphothioate group Chemical group 0.000 description 1
• USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000013933 post-embryonic development Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 229940093625 propylene glycol monostearate Drugs 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000026447 protein localization Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 239000012521 purified sample Substances 0.000 description 1
• 150000003220 pyrenes Chemical class 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 150000004671 saturated fatty acids Chemical class 0.000 description 1
• 235000003441 saturated fatty acids Nutrition 0.000 description 1
• 238000012106 screening analysis Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• 238000004088 simulation Methods 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 230000008410 smoothened signaling pathway Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000004328 sodium tetraborate Substances 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229940012831 stearyl alcohol Drugs 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000000475 sunscreen effect Effects 0.000 description 1
• 239000000516 sunscreening agent Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 235000007586 terpenes Nutrition 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
• WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000010409 thin film Substances 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 239000002691 unilamellar liposome Substances 0.000 description 1
• 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
• 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 101150061422 yip5 gene Proteins 0.000 description 1